Physician profile
Kenneth G Singleton
NPI 1053388355
$2,131.25
in general payments reported to CMS, 2019-2025
29 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $157 · 2021: $616 · 2022: $375 · 2023: $267 · 2024: $237 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.85 | 2019-2024 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $339.79 | 2019-2025 | |
| Aspira Women'S Health INC | $183.38 | 2021 | |
| Astellas Pharma US INC | $115.89 | 2019-2025 | Veozah |
| Shield Therapeutics INC | $79.99 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $73.68 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $72.94 | 2021-2025 | |
| Exeltis, USA INC. | $70.24 | 2021-2023 | Slynd |
| Organon LLC | $67.71 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $61.86 | 2020-2023 | Gardasil 9 |
| Allergan, INC. | $57.93 | 2019-2020 | |
| Davol INC. | $57.64 | 2022 | |
| Scynexis, INC. | $42.24 | 2022 | |
| Pfizer INC. | $41.04 | 2023-2024 | |
| Ethicon US, LLC | $38.28 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $37.91 | 2019-2025 | |
| Avion Pharmaceuticals | $32.06 | 2021 | |
| Hologic Sales and Service, LLC | $29.11 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Biogen, INC. | $25.94 | 2024 | |
| Mylan Pharmaceuticals INC. | $25.64 | 2019-2022 | |
| Meditrina | $24.52 | 2021 | |
| Myovant Sciences INC. | $23.38 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $21.41 | 2024 | Myfembree |
| Becton, Dickinson and Company | $20.04 | 2019 | |
| Lilly USA, LLC | $17.31 | 2025 | Zepbound |
| Medtronic, INC. | $16.97 | 2024 | V-Loc 180 |
| Agile Therapeutics, INC. | $13.35 | 2021 | |
| Lupin INC. | $13.12 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.